Market Place
Sourcing Support
Lupin Gets Tentative US FDA Nod for Oxcarbazepine Tablet
09 Jun 2025 //
EXPRESSPHARMA
Harmony Biosciences Strengthens Patent Position with Settlement
05 Jun 2025 //
BUSINESSWIRE
Girard Sharp and Motley Rice Announce Proposed Settlement
27 May 2025 //
PR NEWSWIRE
Lupin to Present Phase 1 Data on LNP7457 at ASCO Meeting 2025
27 May 2025 //
INDPHARMAPOST
Novartis Offers Payment Plan for High-Cost Heart Medicine
27 May 2025 //
ECONOMICTIMES
Lupin Deal to Supply Biosimilar Ranibizumab in Latin America
26 May 2025 //
ECONOMICTIMES
Lupin partners Honeywell for HFO technology in Inhalers
21 May 2025 //
EXPRESSPHARMA
Lupin to boost complex generics in US, EU; eyes India growth
19 May 2025 //
BUSINESS STD
Lupin receives USFDA approval for Rivaroxaban Tablets
19 May 2025 //
INDPHARMAPOST
Lupin posts consolidated Q4 FY25 PAT at Rs. 772.52 Cr
16 May 2025 //
INDPHARMAPOST
Lupin launches Tolvaptan Tablets in the US
14 May 2025 //
EXPRESS PHARMA
Lupin gains USFDA nod for Raltegravir Tablets USP, 600 mg
09 May 2025 //
EXPRESSPHARMA
Lupin Launches Eslicarbazepine Acetate Tablets in Us
08 May 2025 //
INDPHARMAPOST
Supply chain leadership: Stepping into the spotlight
08 May 2025 //
EXPRESS PHARMA
Lupin`s Generics Raltegravir Receives Approval in US
07 May 2025 //
FDA
Lupin receives US FDA approval for generic Tolvaptan Tablets
25 Apr 2025 //
EXPRESSPHARMA
Lupin recalls nearly 3,000 bottles of OCD drug in US
24 Apr 2025 //
FIERCE PHARMA
Lupin Diagnostics gets NABL accreditation for all new labs
24 Apr 2025 //
INDPHARMAPOST
Dr Reddy`s, Lupin recall products in US for errors: USFDA
22 Apr 2025 //
ECONOMICTIMES
Lupin gets EIR from USFDA for Nagpur injectable facility
17 Apr 2025 //
INDPHARMAPOST
Indian pharma stocks decline after Trump again threatens tariffs
09 Apr 2025 //
REUTERS
Lupin announces acquisition of Renascience Pharma for 12.3M
05 Apr 2025 //
BUSINESS STD
Lupin bags EcoVadis Silver Medal for sustainability excellence
21 Mar 2025 //
INDPHARMAPOST
Lupin`s Generics Rivaroxaban Receives Approval in US
03 Mar 2025 //
FDA
Lupin`s Generics Rivaroxaban Receives Tentative Approval in US
03 Mar 2025 //
FDA
Lupin In S&P Global Sustainability Yearbook 2025 Second Year
02 Mar 2025 //
EXPRESSPHARMA
Nifty Pharma Tanks 3% on Tariff Threat; Zydus, Lupin Down 10%
19 Feb 2025 //
BUSINESS STD
Lupin Q3 FY25 profit up 40% at Rs. 855 Cr
14 Feb 2025 //
INDPHARMAPOST
Lupin receives approval from FDA for Ipratropium Br Nasal Solution
11 Feb 2025 //
INDPHARMAPOST
Lupin receives tentative FDA approval for generic Darunavir
06 Feb 2025 //
EXPRESS PHARMA
Lupin`s Somerset Facility Clears USFDA Inspection With Zero 483
04 Feb 2025 //
BUSINESS STD
Lupin and Avas launch NaMuscla in Italy
29 Jan 2025 //
EXPRESSPHARMA
Lupin gets USFDA nod for generic HIV drug
24 Jan 2025 //
ECONOMICTIMES
Lupin launches Minzoya in the US
14 Jan 2025 //
PRESS RELEASE
Trends 2025: Redefining the pharma supply chain
11 Jan 2025 //
EXPRESSPHARMA
Lupin Gets Tentative U.S. FDA Approval For Ivacaftor Oral Granules
10 Jan 2025 //
EXPRESSPHARMA
Enforcement Report - Week of January 8, 2025
08 Jan 2025 //
FDA
Lupin acquires Huminsulin from Lilly, enhance diabetes portfolio
31 Dec 2024 //
INDPHARMAPOST
Lupin receives FDA tentative approval for HIV treatment generic
07 Dec 2024 //
EXPRESSPHARMA
FDA gives tentative approval to Lupin’s for treat type 2 diabetes
30 Nov 2024 //
FINANCIALXPRESS
Lupin’s Humrahi Diabetes Support Program Expands To Heart Health
28 Nov 2024 //
FINANCIALXPRESS
Enforcement Report - Week of November 27, 2024
27 Nov 2024 //
FDA
Lupin recalls over 6 lakh bottles of hypertension drug in US
26 Nov 2024 //
ECONOMICTIMES
Lupin’s ESG score rises to 76 in S&P Global ESG Ratings
25 Nov 2024 //
EXPRESSPHARMA
Lupin and NAPCON host Walkathon to raise COPD awareness
22 Nov 2024 //
EXPRESSPHARMA
Lupin receives FDA approval for generic version of Adderall XR
21 Nov 2024 //
EXPRESSPHARMA
Lupin launches Bumetanide Injection USP in US
20 Nov 2024 //
PRESS RELEASE
Lupin launches Humrahi with focus on diabetes and heart health
18 Nov 2024 //
EXPRESSPHARMA
Lupin receives tentative FDA approval for Raltegravir tablets
11 Nov 2024 //
EXPRESSPHARMA
Lupin Eyes Double-Digit Growth, Focuses on US Market in FY25
09 Nov 2024 //
CNBCTV
Lupin CFO: Medicine Business Benefits from Supply Chain Diversify
08 Nov 2024 //
CNBC
Lupin Develops Inhalers with Near-Zero Global Warming Propellants
28 Oct 2024 //
PR NEWSWIRE
DoP Rejects Review Applications on Metoprolol Pricing
24 Oct 2024 //
PHARMABIZ
Lupin appoints Claus Jepsen as President of Global Specialty
22 Oct 2024 //
EXPRESSPHARMA
Lupin launches Aptivate Achi Bhookh Fest in Mumbai and Suburbs
16 Oct 2024 //
INDPHARMAPOST
Lupin launches first generic of Pred Forte in the US
16 Oct 2024 //
EXPRESSPHARMA
Lupin and Scope sign agreement for Optase in Mexico
08 Oct 2024 //
INDPHARMAPOST
Lupin`s Pune-based biotech facility gets 5 observations from US FDA
05 Oct 2024 //
BUSINESS STD
Lupin acquires 9 brands of Medical Nutritional Institute in Africa
05 Oct 2024 //
EXPRESSPHARMA
Aytu Partners With Lupin To Commercialize ADHD Drugs In Canada
01 Oct 2024 //
ACCESSWIRE
